H.R.3043 forbids the Department of Health and Human Services from directly or indirectly conducting biomedical research that tests on vertebrate animals in laboratories that are located in or owned or controlled by specified foreign states, and it bars HHS from supporting such animal testing through grants, subgrants, contracts, cooperative agreements, or other funding vehicles. The bill lists the People’s Republic of China (including Hong Kong), Iran, North Korea, and Russia, and lets the Secretary of HHS add other countries after consultation with State and Defense.
For practitioners tracking federal research funding, the bill changes the permissible geography for HHS-supported animal research and would force new compliance controls on grantmaking, contracts, and international collaborations. It also creates a 60-day reporting duty when HHS designates an additional country, which embeds congressional oversight into any expansion of the list.
At a Glance
What It Does
The bill bars HHS from performing or supporting biomedical experiments that involve testing on vertebrate animals in facilities located in, or owned or controlled by, four named countries and any additional nation the Secretary designates after consulting State and Defense. It expressly forbids funding via grants, subgrants, contracts, cooperative agreements, or other funding vehicles to entities based in those countries that carry out vertebrate-animal testing.
Who It Affects
The prohibition targets HHS programs and award mechanisms—most prominently NIH extramural and intramural activities—and any U.S. institutions that subcontract or collaborate with entities based in the named countries. It also affects foreign entities based in those states that currently receive HHS support or partner with U.S. researchers.
Why It Matters
By tying geographic restrictions to funding flows, the bill forces operational changes in grant administration, award terms, and due diligence on international partners. Compliance officers, university research offices, and contractors will need to reassess awards with foreign components and update monitoring to avoid prohibited support.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill establishes two parallel prohibitions. First, it prevents HHS itself from conducting biomedical research or experimentation that involves testing on vertebrate animals in any facility located in—or owned or controlled by—the named foreign states or a subsequently designated country.
That language covers intramural HHS activities and any operational footprint HHS maintains overseas; its reach depends on how broadly "owned or controlled" and "directly or indirectly conduct" are interpreted in practice. Second, the statute forbids HHS from supporting such research through the full range of funding instruments listed in the text: grants, subgrants, contracts, cooperative agreements, and other funding vehicles.
Those terms sweep in routine extramural mechanisms used by NIH and other HHS components.
The bill names four countries explicitly—People’s Republic of China (including Hong Kong), Iran, North Korea, and Russia—and creates a process for adding others. Before designating an additional country, the Secretary must consult with the Secretaries of State and Defense; after making a determination that a country is "of concern," the Secretary must send a detailed report explaining the decision to a specified set of congressional committees within 60 days.
That reporting requirement ties future expansions of the list to both interagency input and congressional oversight.Implementation will be practical and procedural as much as legal. HHS would need to identify award recipients and projects with covered foreign components, revise grant terms and contractor statements of work to prohibit the proscribed activity, and embed screening and certification steps into pre-award and post-award processes.
The text does not create an exception for multinational studies, nor does it define key terms such as "vertebrate animals," "owned or controlled," or the scope of "support" beyond the enumerated funding vehicles—leaving interpretive work to HHS and its legal advisors. Because the bill anchors its prohibitions to HHS authority and funding tools, its principal effects are administrative: changing who HHS will fund and where testing may take place under HHS auspices.
The Five Things You Need to Know
The bill prohibits HHS from conducting or supporting biomedical experiments that involve testing on vertebrate animals in facilities located in, or owned or controlled by, China (including Hong Kong), Iran, North Korea, and Russia.
HHS may not "support" such research through grants, subgrants, contracts, cooperative agreements, or "other funding vehicles," language that explicitly covers the typical instruments used by NIH and other HHS components.
The Secretary of HHS can add other countries, but only after consulting with the Secretary of State and the Secretary of Defense and must submit a detailed report to specified congressional committees explaining the determination.
When the Secretary designates a country under the addition process, HHS must deliver the detailed accounting to six named committees (both Appropriations committees, HELP, Homeland Security and Governmental Affairs, Energy and Commerce, and Homeland Security of the House) within 60 days.
The bill does not define core terms—such as "vertebrate animals," "owned or controlled," or any exemptions—or specify enforcement mechanisms, leaving substantial interpretive and implementation choices to HHS.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Provides the Act’s short name—"Accountability in Foreign Animal Research Act." This is purely formal but important for citation and indexing; future rulemaking, guidance, and reporting will reference the Act by this title.
Ban on HHS conduct of covered animal testing abroad
Bars HHS from directly or indirectly conducting biomedical research or experimentation involving testing on vertebrate animals in any facility that is located in, or owned or controlled (directly or indirectly) by, a covered foreign country. Practically, that prevents HHS intramural programs, HHS employees abroad, and any HHS-managed overseas laboratories from engaging in the proscribed animal testing in those jurisdictions; the "owned or controlled" phrase also reaches foreign facilities under majority ownership, subsidiary control, or similar governance relationships.
Ban on HHS support for covered animal testing
Prohibits HHS from supporting biomedical research or experimentation involving vertebrate-animal testing when the testing is conducted by any entity based in a covered foreign country. The statute lists specific funding channels—grants, subgrants, contracts, cooperative agreements—and adds a catchall "other funding vehicles," which means awards with foreign components, subcontracts with foreign partners, and other pass-through funding mechanisms will need scrutiny and likely revision to ensure compliance.
Enumerated list of covered countries
Specifies four countries to which the prohibitions apply: the People’s Republic of China (including Hong Kong), the Islamic Republic of Iran, the Democratic People’s Republic of Korea, and the Russian Federation. The explicit inclusion of Hong Kong signals congressional intent to treat that Special Administrative Region as subject to the same restrictions as mainland China for the bill’s purposes.
Process and reporting for adding other countries
Allows the Secretary to designate additional countries as subject to the prohibitions after consultation with the Secretaries of State and Defense, and requires HHS to submit a "detailed accounting" of the reasoning for any such determination to six named congressional committees within 60 days. That creates a documentary record and a tight timeline for congressional oversight whenever the list expands, which may constrain secret or sensitive determinations and push interagency coordination into a public, reportable form.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- U.S. national security stakeholders (e.g., Defense and intelligence community): Reduces the risk that HHS funding or U.S.-run animal studies directly enable adversary-controlled facilities and creates a statutory barrier against certain types of outward research support.
- Domestic animal welfare and advocacy organizations: Gains a statutory prohibition on taxpayer support for specified foreign animal testing, which aligns with campaigns seeking limits on overseas animal experimentation funded by U.S. dollars.
- Congressional oversight committees: Strengthened role via the 60-day reporting requirement and the requirement that HHS document the rationale for adding countries, improving transparency around designation decisions.
- U.S.-based competitors to foreign labs: Firms and institutions that compete with or seek to repatriate research may find a more level playing field if certain foreign labs lose access to U.S. collaboration or funding.
Who Bears the Cost
- NIH-funded researchers and university research offices with foreign collaborations: Must re-scope projects, terminate or reassign foreign components based in the named countries, and update subaward compliance processes—driving administrative costs and potential disruption to ongoing studies.
- HHS program and grants management offices: Face increased compliance burdens to identify covered foreign components, draft new award terms, perform due diligence on ownership/control of foreign entities, and manage reporting obligations when countries are added.
- Foreign institutions and partners based in the listed countries: Lose access to HHS funding and official collaboration channels for projects that involve vertebrate-animal testing, which may sever or reduce existing partnerships with U.S. researchers.
- Multinational research consortia and global health programs: Risk project delays or redesigns when components occur in a covered jurisdiction, with potential consequences for time-sensitive work such as infectious disease studies.
Key Issues
The Core Tension
The bill pits two legitimate objectives: protecting national security and ensuring taxpayer funds do not underwrite perceived adversary capabilities versus preserving the openness and effectiveness of international scientific collaboration. Tight geographic restrictions reduce risks of unintended support to hostile states, but they also fragment research networks, complicate multinational studies, and shift compliance costs onto grantees and HHS—creating a trade-off between security-driven containment and the operational realities of globally integrated science.
The statute’s short, categorical prohibitions leave several important technical questions unresolved. Key terms are undefined: "vertebrate animals" is central to scope but not clarified, creating questions about embryonic stages, model organisms, and nontraditional vertebrate systems. "Owned or controlled, directly or indirectly," and "based in" will drive how HHS treats subsidiaries, joint ventures, and multinational entities; absent regulatory definitions, agencies will need to craft criteria for corporate affiliation and control that can be litigated.
The bill also uses a broad "other funding vehicles" phrase that gives HHS interpretive work to determine which instruments beyond the listed types fall within the ban.
Operationally, the measure forces HHS to build screening and monitoring processes that do not currently exist at scale. Agencies will need to map foreign components in awards, adjust terms and conditions, and decide whether self-certifications, audits, or contractual flow-down clauses suffice to prevent prohibited support.
The 60-day congressional reporting window for new designations ensures oversight but may be impractically short for classified consultations with Defense or State or for documenting complex ownership structures. Finally, the bill contains no enforcement regime or penalty structure beyond the prohibitions themselves, leaving open how HHS will pursue violations, whether through termination of awards, recoupment, or other administrative remedies.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.